A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04557098)

🧪 Interventions in This Study

• Teclistamab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (51 Sites)

Showing the first 25 of 51 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope — Duarte, California
• University of California San Francisco — San Francisco, California
• Stanford University Medical Center — Stanford, California
• Winship Cancer Institute Emory University — Atlanta, Georgia
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
• Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects — New York, New York
• Memorial Sloan-Kettering Cancer Center — New York, New York
• Levine Cancer Institute — Charlotte, North Carolina
• University of Pennsylvania — Philadelphia, Pennsylvania
• Universitair Ziekenhuis Gent - UZ GENT — Ghent,
• Universitaire Ziekenhuizen Leuven — Leuven,
• Arthur J E Child Comprehensive Cancer Centre — Calgary, Alberta
• Cross Cancer Institute — Edmonton, Alberta
• University Health Network UHN Princess Margaret Cancer Centre — Toronto, Ontario
• McGill University Health Centre — Montreal, Quebec
• Peking University First Hospital — Beijing,
• West China Hospital Si Chuan University — Chengdu,
• Sun Yat -Sen University Cancer Center — Guangzhou,
• First affiliated Hospital of Zhejiang University — Hangzhou,
• Shanghai Changzheng Hospital — Shanghai,
• Shengjing Hospital Of China Medical University — Shenyang,
• Tianjin Medical University Cancer Institute and Hospital — Tianjin,
• The Second Affiliated Hospital of Xi'an Jiaotong University — Xi'an,
• Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez — Lille,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hematological Malignancies

• Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
• Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — Houston, Texas
• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
• Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama

Explore by condition: All Hematological Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.